Table 3.
Positivity of each antibody among all samples, and by HRP-2 antigenemia and PET-PCR status
| By HRP-2 antigenemia result | By PET-PCR result | ||||||
|---|---|---|---|---|---|---|---|
| Antibody Target | Percent positive (n=496) |
HRP-2 positive (n=406) |
HRP-2 negative (n= 90) |
Chi-SQ* | PET-PCR positive (n = 195) |
PET-PCR negative (n = 89) |
Chi-SQ* |
| GlurpRo | 69.6 % (65.5–73.6) |
77.1% (72.7–81.1) |
35.6% (25.7–46.4) |
P <0.001 | 80.0% (73.6–85.4) |
49.4% (38.7–60.3) |
P <0.001 |
| HRP2 | 9.5 % (7.1–12.4) |
9.4% (6.7–12.6) |
10.0% (4.7–18.1) |
P = 0.85 | 9.7% (6.0–14.8) |
10.1% (4.0–17.0) |
P = 0.84 |
| LSA1 | 37.2 % (32.9–41.7) |
42.9% (38.0–47.9) |
11.4% (5.6–19.9) |
P <0.001 | 45.6% (38.5–52.9) |
18.6% (11.0–28.5) |
P <0.001 |
| AMA1 | 78.3 % (74.4–81.9) |
82.5% (78.5–86.1) |
59.1% (48.1–69.5) |
P <0.001 | 87.7% (82.2–92.0) |
54.7% (43.6–65.4) |
P <0.001 |
| CSP | 59.3 % (54.8–63.7) |
64.8% (59.9–69.5) |
34.1% (24.3–45.0) |
P <0.001 | 74.4% (67.6–80.3) |
32.6% (22.8–43.5) |
P <0.001 |
| MSP1 | 85.5 % (82.0–88.5) |
89.5% (86.1–92.4) |
67.0% (56.2–76.7) |
P <0.001 | 91.8% (87.0–95.2) |
72.1% (61.4–81.2) |
P <0.001 |
| StarpR | 17.7 (14.5–21.4) |
21.2% (17.3–25.2) |
2.2% (0.3–7.8) |
P <0.001 | 23.1% (17.4–29.6) |
5.6% (1.9–12.6) |
P =0.0003 |
| SALSA | 10.7 (8.1–13.7) |
12.3% (9.3–15.9) |
3.3% (0.7–9.4) |
P = 0.005 | 12.8% (8.5–18.3) |
2.3% (0.3–7.9) |
P =0.005 |
*
Exact confidence limits